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Licorice ingestion, as well as mutations in the HSD11B2 gene, inhibits 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2)
enzyme activity, causing the syndrome of apparent mineral corticoid excess (AME). However, the combined eﬀect of licorice
ingestion and an HSD11B2 mutation has never been reported, until now. In this study, we demonstrated that licorice ingestion
can produce overt hypertension in an individual without medical history of hypertension who is heterozygous for wild-type and
mutant HSD11B2 genes. Our patient was a 51-year-old female with serious hypertension who had been taking herbal medicine
containinglicoricefor morethan oneyear. She wasclinicallydiagnosed ashavinglicorice intoxication,because shedid notpresent
with hypertension after ceasing the herbal medicine. Molecular analysis showed that she carried a missense mutation, c.40C>T,
in HSD11B2. In conclusion, licorice ingestion is an environmental risk factor for hypertension or AME state in patients with a
mutation in HSD11B2. Carrying a mutation in HSD11B2 is, conversely, a genetic risk factor for licorice-induced hypertension or
AME state. Herbal medicine containinglicorice may, therefore, be contraindicated in patients with an HSD11B2 mutation.
1.Introduction
Licorice (Glycyrrhizae radix) has a long history of use in
herbalmedicineortraditionalmedicineofEastAsia.Licorice
has been used in combination of other herbal ingredients
to harmonize and improve the eﬀects of herbal remedy.
Many researchers are now studying the eﬀectsoflicoricewith
scientiﬁc experiments on animals or cultured cells. Recently,
cytoprotective eﬀect of licorice has been reported [1, 2].
On the other hand, licorice has been known for decades
to cause mineralocorticoid-like adverse eﬀects including
hypertension, edema, heart failure or hypokalemia, even
though patients have low circulating levels of aldosterone
[3]. Recent studies revealed that licorice inhibits the
enzyme activity of 11β-hydroxysteroid dehydrogenase type
2( 1 1 βHSD2), resulting in a pathological state similar to
mineralocorticoid excess named apparent mineralocorticoid
excess state (AME; [4–6]). In licorice-induced hypertension,
glycyrrhetinic acid, the active substituent of licorice, inhibits
11βHSD2 resulting in AME state [3, 7]. Thus, it appears
that licorice intoxication is a reversible pharmacological
counterpart to AME syndrome, an inherited form of AME
state caused by deﬁciency of 11βHSD2 enzyme activity [3].
The 11βHSD2 enzyme mainly converts cortisol into
cortisone [3, 7, 8]. Of these two hormones, only cortisol
has aﬃnity to mineralocorticoid receptors, and thus induces
mineralocorticoideﬀects.Inseveralhypertensivesyndromes,
ad e c r e a s ei n1 1 βHSD2 activity has been described as a
pathogenetic mechanism of increased blood pressure. Muta-
tionsinthegeneHSD11B2codingfor11βHSD2compromise2 Evidence-Based Complementary and Alternative Medicine
11βHSD2 enzyme activity, resulting in juvenile or late-onset
forms of the AME syndrome [9, 10].
AME syndrome is an autosomal recessive disorder;
homozygous or compound heterozygous mutations in the
HSD11B2 gene, encoding 11βHSD2, have been identiﬁed
in patients [9–14]. Heterozygosity for wild and mutant
HSD11B2 alleles does not cause AME state or hyperten-
sion [9, 15], although some parents of AME patients are
heterozygous for a mutation presented with a phenotype
indistinguishable from “essential” hypertension [10].
However, the combined eﬀect of licorice ingestion and
the HSD11B2 mutation has never been reported. Herbal
medicine is very popular in Japan and many remedies
availablein Japan contain licorice. However, thefrequency of
the HSD11B2 mutation carriers in the Japanese population
is ∼1% [16]. Thus, it is curious that HSD11B2 mutation
has not been reported among Japanese patients with licorice
intoxication, and that the combined eﬀect of licorice inges-
tion and the HSD11B2 mutation has never been previously
discussed.
In this study, we demonstrated that licorice ingestion
can produce overt hypertension in an individual who is
heterozygousfor wild-type and mutant HSD11B2 geneswith
no history of hypertension. This indicates a combined eﬀect
of licorice ingestion and the HSD11B2 mutation.
2.Methods
2.1. Patient. The patient was a 51-year-old female with a
two-year history of postmenopausal syndrome. Her weight
andheight were 49kgand 153cm. Toimprove thesymptoms
of postmenopausal syndrome, she had been taking an herbal
medicine, Shimotu-ka-ninjin-kanzo-to, that is, four herbs
(Rehmannia, Cnidium, Paeonia and Angelica) plus ginseng
and licorice decoction for more than one year. Her daily
ingestion of licorice was less than 1.0g. She did not show
hypertension in her medical history. Her systolic blood
pressure was usually measured to be less than 130mmHg.
On April 15, 2006, she was admitted to a medical oﬃce
withaheavyheadachelastingseveralhours.Onexamination,
her blood pressure while sitting was 190/110mmHg. She
was just instructed to rest quietly in bed at home and
to stop taking the herbal medicine. Her blood pressure
stabilized to within normal limits the following day. She
did not take the herbal medicine after this episode and did
not experience hypertension again. Although other clinical
examinations apart from blood pressure measurement were
notperformed, itwasstrongly suspected thatherparoxysmal
hypertension was associated with licorice intoxication.
2.2. Molecular Analysis. Informed consent was obtained
from the patient before the analysis. Genomic DNA
was extracted from EDTA whole blood sample using a
commercially available DNA extraction kit. Each exon
of HSD11B2 was PCR-ampliﬁed with the primer pairs
reported previously [9], followed by denaturing high-
performance liquid chromatography (DHPLC) screening
and direct sequencing according to our previous reports
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peak
Figure 1: DHPLC screening for a mutation in the HSD11B2 gene.
Screening showed a small and large peak on the chromatogram
of HSD11B2 exon 1, while controls showed a single peak. The
small peak indicated heteroduplex DNA formation, suggesting the
presence of a mutation in the patient’s HSD11B2 exon 1.
[17]. DHPLC screening for the HSD11B2 mutation,
c.40C>T, was performed with primers as described
below: 5 -GCTGGGCCGCCATGGAGC-3  and 5 -
CGGGACAACGCGATCCAGC-3 .
3.Results
3.1. DHPLC Screening for a Mutation in HSD11B2. DHPLC
screening showed that the patient had a nucleotide mutation
in the PCR fragment including HSD11B2 exon 1. As shown
in Figure 1, the patienthad two peaks inher DHPLC chart of
the PCR fragment including HSD11B2 exon 1. This ﬁnding
suggested that the patient carried nucleotide changes in this
region. However, DHPLC screening did not disclose what
kind of mutation was present in the patient.
3.2. Identiﬁcation of the Mutation in HSD11B2. To identify
the mutation in the patient, we conducted a direct DNA
sequencinganalysisofthePCRfragmentincludingHSD11B2
exon 1. As shown in Figure 2, the patient carried a missense
mutation, c.40C>T, leading to an amino acid substitution
from leucine to phenylalanine at position 14 of 11βHSD2
(p.L14F). Figure 2 also demonstrates that the patient was
heterozygousfor normal and mutant alleles. In other regions
of the HSD11B2 gene, no nucleotide change was observed in
the patient.
4.Discussion
4.1. Heterozygous Mutation in HSD11B2. We identiﬁed a
heterozygous missense mutation, c.40C>T, in the HSD11B2Evidence-Based Complementary and Alternative Medicine 3
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GGCGCCTGGCTG TCGTGGCTGCCCGC
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G GCGCCTGGCTG TCGTGGCTGCCCGC
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(a) Direct sequencing data
Amino acid sequence surrounding the mutation (b)
Figure 2: Direct DNA sequencing of HSD11B2exon1(a) andaminoacidsequence surrounding the mutation(b).DNA sequencing showed
heterozygous status for the wild-type (C at nucleotide position 40) and mutant (T at nucleotide position 40) sequences.
gene in a Japanese patient with licorice-induced hyper-
tension. Kamide et al. [16] ﬁrst reported the c.40C>Ti n
HSD11B2 exon 1 in the Japanese population.They found the
mutation in 11 out of 2433 hypertensive individuals and in
8 out of 2175 normotensive individuals. Althoughthere have
notbeenreportsofenzymeactivityofmutated11βHSD2nor
AME patients homozygous for the mutation, this mutation
occurs in the amino acid residue that is highly conserved
among three diﬀerent species (human, mouse and rabbit),
indicating that the mutation may aﬀect 11βHSD2 activity
[16].
In general, heterozygosity for wild and mutant HSD11B2
alleles does not play a critical role in the pathogenesis of
AME state in most cases [9, 15]. Lavery et al. [10]n o t e d
that the mothers of AME patients heterozygous for missense
mutations presented with a phenotype indistinguishable
from essential hypertension. Taken together, all of these
ﬁndings suggested that one copy of normal HSD11B2 allele
may guarantee enough levels of 11βHSD2 enzyme activity to
prevent serious AME syndrome and that factors other than
HSD11B2 mutation may be required for the development of
hypertension or AME in heterozygous patients.
4.2. Licorice Ingestion as an Environmental Risk Factor.
A question then arises as to why our patient showed
hypertension despite being heterozygous for an HSD11B2
mutation. The most likely explanation is that the licorice in
the herbal medicine inhibited the residual enzyme activity of
normal 11βHSD2 in the patient, causing paroxysmal heavy
headache asa symptom ofAMEstate. Thus,we can speculate
that licorice ingestion contributed to the development of
hypertension in this patient (Figure 3).
4.3. Carrying a Mutation in HSD11B2 as a Genetic Risk
Factor. It is also noteworthy that our patient had been
ingesting no more than 1.0g of licorice per day for only
one year before the paroxysmal hypertension. Yasue et
al. [18] reported that a 93-year-old hypertensive female,
taking herbal medicines containing licorice, suﬀered from
severe hypokalemia, rhabdomyolysis, muscle paralysis and
respiratory impairment due to a serious AME state. She
had been ingesting 5.0g of licorice daily for the last seven
years. Gerritsen et al. [19] also reported that a 44-year-old
previously healthy female, was admitted to the emergency
department following resuscitation from ventricular ﬁbrilla-
tion. She had been ingesting 250–500g of licorice daily for
the several years. Compared with these patients, our patient
suﬀered from licorice intoxication after consuming a very
small amount of licorice, which suggested that the presence
of an HSD11B2 mutation contributed to the development of
her hypertension (Figure 3).
It may be hazardous for such patients with an HSD11B2
mutation to take herbal medicine containing licorice. To
avoid serious side eﬀects of licorice, pharmacogenetic
approaches are required. It has been reported that an A-
to-G change at nucleotide 1555 in mitochondrion DNA is
associated with aminoglycoside-induced hearing loss [20].
Now,genetictestingofmitochondrionDNAiswidelyusedto4 Evidence-Based Complementary and Alternative Medicine
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Figure3:Schematicdrawingofthepathogenesisofthepatient.ThepatientwasheterozygousforamutationinHSD11B2(“normal/mutant”
alleles in the ﬁgure), suggesting that her 11βHSD2 enzyme activity in the kidney was reduced. Without licorice loading, she was able to keep
her healthy condition. However, with licorice loading, she showed serious hypertension.
avoidhearing loss caused by aminoglycosides [21]. Similarly,
genetic testing of HSD11B2 will be useful to avoid licorice-
induced hypertension or AME state.
5.Conclusion
We applied a pharmacogenetic approach to licorice intox-
ication and were the ﬁrst to identify the combined eﬀect
of licorice ingestion and an HSD11B2 mutation. Licorice
ingestion is an environmental risk factor for hypertension or
AMEstateinpatientswithamutationinHSD11B2.Carrying
am u t a t i o ni nHSD11B2 is therefore, conversely, a genetic
risk factor for licorice-induced hypertension or AME state.
Herbal medicine containing licorice may be contraindicated
for patients with an HSD11B2 mutation. Genetic testing to
detect individuals with an HSD11B2 mutation will be useful
to avoid licorice-induced adverse eﬀects.
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